ArticleJournal of pharmaceutical sciences2021
Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships.
Article in Journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Demographic disparities in access to COVID-19 clinical trial sites across the United States: a geospatial analysis.International journal for equity in health · 2025Article
- Occupational hygiene risk assessment at light speed-a study for protecting worker health and safety in the biopharmaceutical industry.Frontiers in public health · 2025Review
- mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions.Vaccines · 2023Review
- An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies.Environmental innovation and societal transitions · 2023Article
- Biopharma innovation trends during COVID-19 and beyond: an evidence from global partnerships and fundraising activities, 2011-2022.Globalization and health · 2023Observational
- Clinical Features of COVID-19 Vaccine-Associated Autoimmune Hepatitis: A Systematic Review.Diseases (Basel, Switzerland) · 2023Review
- COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy.Translational research : the journal of laboratory and clinical medicine · 2023Review
- Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development.Pathogens (Basel, Switzerland) · 2022Review
- The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas.Kansas journal of medicine · 2022Article
- A review of COVID-19's impact on modern medical systems from a health organization management perspective.Health and technology · 2022Review
- Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.Advanced drug delivery reviews · 2021Review
- Implications of attitudes and beliefs about COVID-19 vaccines for vaccination campaigns in the United States: A latent class analysis.Preventive medicine reports · 2021Article
- Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness.Bioengineering (Basel, Switzerland) · 2021Article
- The COVID-19 Vaccine: Why the Hesitancy?Journal of radiology nursing · 2021Article
- Response to: Regarding the Article: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.Archives of medical research · 2021Article
- The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations.American journal of obstetrics and gynecology · 2021Review
- Review
- Educational aspects of rare and orphan lung diseases.Respiratory research · 2021Review
- Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.Journal of pharmaceutical sciences · 2021Article
- Rapid growth in the COVID-19 era.MRS bulletin · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
It is anticipated that effective vaccines will enable the resumption of social and economic normalcy. Current calls for masking, social distancing and other restrictive measures for the public-good are difficult to enforce and are unstainable. As ~2-4% of the 50 million SARS-CoV2-infected have succumbed to Covid-19, the US department of Health and Human Services has organized a public-private partnership called Operation Warp Speed (OWS) to develop, produce and deliver 300 million doses of safe and effective vaccines with a January 2021 target. While a majority of the 300+ Covid-19 vaccine candidates are in various stages of preclinical and early-stage clinical testing, 6 clinical candidates are supported with over 10 billion USD plus integrated resources under the OWS agenda. This unprecedented approach is investing in the manufacture of product candidates ahead of product approval. It is enabled by new gene and recombinant pharmaceutical platform technologies that are accelerating the clinical study timeline from ~10 to less than 1 year. It is anticipated that one or more of the 6 candidates under the OWS initiative will be safe, effective and provide a sustained immune response to prevent infection and disease progression. This way, social and economic activities could return to normalcy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.